Physician profile
Susan Mathison
NPI 1952469165
$11,436.10
in general payments reported to CMS, 2019-2025
28 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $234 · 2021: $3,551 · 2022: $2,612 · 2023: $1,117 · 2024: $2,673 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,003 · Food and Beverage: $949 · Gift: $3.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,002.91 |
| Food and Beverage | $948.95 |
| Gift | $3.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,516.27 | 2019-2021 | |
| Acclarent, INC | $2,465.79 | 2024 | |
| Medical Device Business Services, INC. | $2,439.12 | 2022 | |
| Stryker Corporation | $1,646.94 | 2020-2023 | Scopis Ent, Clarifix Cryotherapy Device |
| Galderma Laboratories, L.P. | $795.36 | 2019-2024 | |
| Allergan, INC. | $612.28 | 2019-2021 | |
| Aerin Medical INC. | $399.22 | 2020-2023 | |
| Inspire Medical Systems, INC. | $89.74 | 2024 | Inspire |
| Phadia US INC. | $50.23 | 2023-2025 | Immunocap |
| Merz North America, INC. | $44.59 | 2019-2020 | |
| Revance Therapeutics, INC. | $39.52 | 2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $33.05 | 2025 | Dupixent |
| Lilly USA, LLC | $30.98 | 2024-2025 | Ebglyss, Taltz |
| Takeda Pharmaceuticals U.S.A., INC. | $23.14 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $22.64 | 2025 | Gardasil 9, Capvaxive |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $21.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.95 | 2021 | |
| Genzyme Corporation | $19.74 | 2022 | |
| Janssen Biotech, INC. | $19.62 | 2024 | Tremfya |
| Glaxosmithkline, LLC. | $18.13 | 2022 | |
| Optinose US, INC. | $18.11 | 2024 | |
| Ucb, INC. | $17.82 | 2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $17.18 | 2023 | Sotyktu |
| Astrazeneca Pharmaceuticals Lp | $16.97 | 2025 | Breztri |
| Organogenesis INC. | $16.33 | 2023 | Puraply |
| Amgen INC. | $15.77 | 2021 | |
| Abbvie INC. | $13.36 | 2023 | |
| Pfizer INC. | $13.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Mathison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.